Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024. “This was another very strong quarter for Twist with both revenue and orders increasing to $75.3 million and $93.2 million, respectively,” said Emily M. Leproust, Ph.D., CE
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks